Pai Holding, Ll Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pai Holding, Ll (US): 11 reconciled FDA prescription therapies, $21.0M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies11
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$21.0M
2024 Medicare Part D Spend$10.9M
2024 Medicaid Spend$10.1M
California HCAI SB 17 Filings15 WAC filings (max 171.7% 2-yr change)